MAGEA4 Antibody

1. MAGEA4 was positively correlated with TWIST1, and its knockdown inhibited EMT in TE3 cells. PMID:28653599
2. Because of the significant correlation of MAGEA4 and indices of poor prognosis, the role of this CTA may be confirmed in Esophageal squamous cell carcinoma (ESCC) aggressiveness and metastasis. Therefore, MAGEA4 may be a promising therapeutic candidate for suppressing ESCC aggressiveness PMID:30197348
3. Study shows that whereas MAGEA4 expression by itself may be indicative of a poor prognosis in primary lung cancer, its prognostic value depends entirely on its subcellular localization and on the p53 status. The accumulation of nuclear MAGEA4 expression without p53 expression is significantly associated with poor survival, implying that MAGEA4 inhibits apoptosis and increases tumorigenesis. PMID:29901069
4. MAGE-A4 depletion from MAGE-A4-expressing cancer cells destabilizes RAD18. PMID:27377895
5. Our results support...the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma PMID:28744588
6. some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers. PMID:27140836
7. Anti-MAGEA4 exhibited the highest sensitivity for detecting early stage colorectal cancer (CRC) and advanced adenoma. PMID:26909861
8. High MAGE-A4 expression is associated with Lung Cancer. PMID:27793776
9. Results found concomitant overexpression of MAGEA4 and TWIST1 in esophageal squamous cell carcinoma (ESCC). Also, it showed a correlation between MAGEA4 and TWIST1 expression, which was found as indirect binding of TWIST1 to the E-boxes in the MAGEA4 promoter revealing transcriptional upregulation of MAGEA4 by TWIST1. PMID:27533647
10. Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas. PMID:27993576
11. CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors. PMID:26191258
12. HLA class I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in non-small cell lung cancer . PMID:23124547
13. Expression of MAGE-A4 may make immunotherapeutic intervention possible in selected patients with thyroid cancer. PMID:24238058
14. Detection of MAGE-4 transcripts in blood may help to predict the prognosis and monitoring of the response of HCV-infected hepatocellular carcinoma patients to therapy PMID:22653756
15. Mage-A4 expression and serum identification is and potential therapeutic target in estrogen receptor negative breast cancer. PMID:23172894
16. MAGEA4 promotes growth by preventing cell cycle arrest and by inhibiting apoptosis mediated by the p53 transcriptional targets. PMID:22842486
17. High MAGE-4 gene expression is associated with metastases in hepatitis C virus patients complicated by hepatocellular carcinoma. PMID:21452042
18. MAGE-A4 is identified as a specific biomarker of esophageal squamous cell carcinoma with a possible oncogenic role contributing to tumor progression. PMID:21613820
19. novel HLA-A2-restricted T cell epitope derived from MAGE-4 was identified PMID:21815906
20. High MAGE-A4 gene expression is associated with head and neck squamous cell carcinoma PMID:20715104
21. Report immunohistochemical expression of MAGE-A4 in renal oncocytoma and chromophobe renal cell carcinoma. PMID:20591578
22. positive expression in patients with non-small cell lung cancer is associated with poorer overall survival PMID:19545928
23. MAGE-4 protein may have a role in development of hepatocellular carcinogenesis in cirrhotic patients PMID:11985796
24. MAGE-A4 expression in bladder transitional cell carcinoma. PMID:12209610
25. strong MAGE-A4 expression and to a lesser degree NY-ESO-1 expression is characteristic of the vast majority of uterine carcinosarcomas and a major subset of papillary serous carcinomas PMID:12209997
26. MAGE-A4 binds to gankyrin and suppresses its oncogenic activity. PMID:12525503
27. a cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis PMID:14739298
28. MAGE-A4(143-151) and SAGE(715-723) are HLA-A2402-restricted CTL epitopes PMID:16061876
29. Expression may represent potential targets for cancer immunotherapy in patients with non small cell lung carcinoma. PMID:16596224
30. Expressed in a large part of epithelial skin tumors with predominantly scattered immunoexpression pattern in organ-transplant recipients. PMID:17214847
31. Its expression is significantly associated with prognostic factors in poor outcome of the non-small cell lung cancer. PMID:18982744
32. Overexpression of MAGE-A4 is associated with bladder cancer. PMID:19533752

Show More

Hide All

HGNC: 6802

UNIGENE: Hs.37107

KEGG: hsa:4103

STRING: 9606.ENSP00000276344

OMIM: 300175